Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro

Antiviral Research

Volumn 59, Issue 1, 2003, Pages 41-47

  Lin, Jung Chung ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Antigen synthesis; Epstein Barr virus; Glycyrrhizic acid; Replication

Indexed keywords

GLYCYRRHIZA EXTRACT; GLYCYRRHIZIC ACID; VIRUS DNA;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EPSTEIN BARR VIRUS; EXPERIMENT; GLYCYRRHIZA; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

GLYCYRRHIZA; HUMAN HERPESVIRUS 4; LIGUSTICUM;

EID: 0038460836     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00030-5     Document Type: Article

References (33)

1. Abe N., Ebina T., Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 26:1982;535-539.
2. Arase Y., Ikeda K., Murashima N., Chayama K., Tsubota A., Koida I., Suzuki Y., Saitoh S., Kobayashi M., Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 79:1997;1494-1500.
3. Baba M., Shigeta S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Res. 7:1987;99-107.
4. Crance J.M., Leveque F., Biziagos E., van Cuyck-Gandre H., Jouan A., Deloince R. Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 23:1994;63-76.
5. de Thé, G., 1982. Epidemiology of Epstein-Barr virus and associated diseases. In: Roizman, B. (Ed.), The Herpesvirus, vol. 1. Plenum Press, New York, pp. 25-87.
6. Finney R.S.H., Somers G.F. The anti-inflammatory activity of glycyrrhetinic acid and derivatives. J. Pharmacol. 10:1958;613-620.
7. Fujisawa K., Watanabe Y., Kimura K. Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med. J. 23:1980;754-756.
8. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J. Bacteriol. 91:1966;1248-1256.
9. Ito M., Nakashima H., Baba M., Pauwels R., De Clercq E., Shigeta S., Yamamoto N. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV(HTLV-III/LAV)]. Antiviral Res. 7:1987;127-137.
10. Ito M., Sato A., Hirabayashi K., Tanabe F., Shigeta S., Baba M., De Clercq E., Nakashima H., Yamamoto N. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral Res. 10:1988;289-298.
11. Lin J.-C., Machida H. Comparison of two bromovinyl nucleoside analogs 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil and E-5-(2-bromovinyl)-2′-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimicrob. Agents Chemother. 32:1988;1068-1072.
12. Lin J.-C., Raab-Traub N. Two strain of Epstein-Barr virus (B95-8 and a P3HR-1 subclone) that lack defective genomes induce early antigen and cause abortive infection of Raji cells. J. Virol. 61:1987;1985-1991.
13. Lin J.-C., Shaw J.E., Smith M.C., Pagano J.S. Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology. 99:1979;183-187.
14. Lin J.-C., Smith M.C., Pagano J.S. Effects of 12-O-tetradecanoyl-phorbol-13-acetate on cell proliferation and Epstein-Barr virus DNA replication. Virology. 117:1982;186-194.
15. Lin J.-C., Smith M.C., Cheng Y.-C., Pagano J.S. Epstein-Barr virus: inhibition of replication by three new drugs. Science. 221:1983;578-579.
16. Lin J.-C., Smith M.C., Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50:1984;50-55.
17. Lin J.-C., Smith M.C., Pagano J.S. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrob. Agents Chemother. 27:1985;971-973.
18. Lin J.-C., De Clercq E., Pagano J.S. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agents Chemother. 31:1987;1431-1433.
19. Lin J.-C., Zhang Z.-X., Smith M.C., Biron K., Pagano J.S. Anti-human immunodeficiency virus agent 3′-azido-3′-deoxythymidine inhibits replication of Epstein-Barr virus. Antimicrob. Agents Chemother. 32:1988;265-267.
20. Lin J.-C., De Clercq E., Pagano J.S. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35:1991;2440-2443.
21. Lin J.-C., Reefschlager J., Herrmann G., Pagano J.S. Evaluation of structure-activity relations between (E)-5-(2-bromovinyl) and 5-vinyl-1-β-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication. Antiviral Res. 17:1992;43-52.
22. Lin J.-C., Lin S.-C., De B.K., Chan W.-P., Evatt B.L. Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease. Blood. 81:1993;3372-3381.
23. Mar E.-C., Chu C.-K., Lin J.-C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res. 28:1995;1-11.
24. Nonoyama M., Pagano J.S. Replication of viral DNA and breakdown of cellular DNA in Epstein-Barr virus infection. J. Virol. 9:1972;714-716.
25. Numazaki K., Nagata N., Sato T., Chiba S. Effect of glycyrrhizin cyclosporin A, and tumor necrosis factor α on infection of U-937 and MRC-5 cells by human cytomegalovirus. J. Leukoc. Biol. 55:1994;24-28.
26. Pagano, J.S., 1991. Gertrude and Werner Henle lecture on viral oncology. In: Ablashi, D.V., et al. (Eds.), Epstein-Barr Virus and Human Disease. The Humana Press, Totowa, NJ, pp. 19-32.
27. Pagano, J.S., 1995. Epstein-Barr virus: therapy of active and latent infection. In: Jeffries, D.J., De Clercq, E. (Eds.), Antiviral Chemotherapy. Wiley, Chichester, UK, pp. 155-195.
28. Pompei R., Flore O., Marccialis M.A., Pani A., Loddo B. Glycyrrhic acid inhibits virus growth and inactivates virus particles. Nature. 281:1979;689-690.
29. Raab-Traub N. Pathogenesis of Epstein-Barr virus and its associated malignancies. Semin. Virol. 7:1996;315-323.
30. Sato H., Goto W., Yamamura J., Kurokawa M., Kageyama S., Takahara T., Watanabe A., Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res. 30:1996;171-177.
31. Shinada M., Azuma M., Kawai H., Sazaki K., Yoshida I., Yoshida T., Suzutani T., Sakuma T. Enhancement of interferon-γ production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Proc. Soc. Exp. Biol. Med. 181:1986;205-210.
32. Suzuki H., Ohta Y., Takino T., Fujisawa K., Hirayama D. Effects of glycyrrhizin on biomedical tests in patients with chronic hepatitis-double blind trial. Asian Med. J. 26:1983;423-438.
33. Utsunomiya T., Kobayashi M., Pollard R.B., Suzuki F. Glycyrrhizin an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob. Agents Chemother. 41:1997;551-556.